Eli Lilly is in talks to buy Kelonia Therapeutics for $2B+, boosting its oncology pipeline with next-gen CAR-T for multiple myeloma.
You are being redirected to the original discussion. Please continue if you want to read the full post.
Continue to original articleYou will be redirected in 3 seconds.